Working… Menu

Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00471133
Recruitment Status : Completed
First Posted : May 9, 2007
Last Update Posted : June 7, 2011
Memorial Sloan Kettering Cancer Center
Information provided by:
Ichor Medical Systems Incorporated

Brief Summary:
The purpose of this study is to evaluate the safety and immunogenicity of a DNA vaccine encoding a melanosomal antigen in melanoma patients at risk for disease progression or recurrence. In this study, the vaccine will be administered intramuscularly using a device that applies brief electrical fields to the tissue at the site of injection (a technique known as electroporation). It is expected that this device will improve the delivery of the vaccine. This study is being performed to determine if this procedure can be administered safely and if it is capable of inducing immune responses to the vaccine.

Condition or disease Intervention/treatment Phase
Melanoma (Skin) Intraocular Melanoma Biological: Xenogeneic Tyrosinase DNA Vaccine Device: TriGrid Delivery System for Intramuscular Electroporation Phase 1

Detailed Description:

This study is designed to evaluate administration of a xenogeneic DNA vaccine encoding the melanosomal antigen tyrosinase by in vivo electroporation in patients with malignant melanoma. The objectives of the study are to characterize the safety and immunogenicity of a DNA vaccine encoding the murine tyrosinase gene delivered administered intramuscularly using the electroporation based TriGrid Delivery System (Ichor Medical Systems). We will assess the nature, frequency, and severity of any toxicity associated with vaccination at escalating pINGmuTyr doses and then expand enrollment at then expand enrollment at the Maximum Tolerated Dose to assess immunologic responses to the tyrosinase antigen.

The hypotheses being tested are that the procedure is feasible and safe and that it induces immune responses specific for tyrosinase in patients with stage IIB-IV malignant melanoma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ia/Ib Study of the Safety and Immunogenicity of a Xenogeneic Tyrosinase DNA Vaccine Melanoma
Study Start Date : April 2007
Actual Primary Completion Date : May 2010
Actual Study Completion Date : May 2010

Arm Intervention/treatment
Experimental: Xenogeneic Tyrosinase Biological: Xenogeneic Tyrosinase DNA Vaccine
Device: TriGrid Delivery System for Intramuscular Electroporation

Primary Outcome Measures :
  1. Evaluate the safety and feasibility of electroporation mediated intramuscular delivery of a mouse tyrosinase plasmid DNA vaccine in patients with stage IIB, IIC, III, or IV melanoma. [ Time Frame: one year ]

Secondary Outcome Measures :
  1. Assess patients with measurable tumor for evidence of anti-tumor response following immunization. [ Time Frame: 6 months ]
  2. Assess the magnitude and frequency of tyrosinase specific immunologic responses in the immunized patients [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have documented, histologically confirmed malignant melanoma, American Joint Commission on Cancer (AJCC) Stage IIB- IV. Patients with stage IIb-III disease are only eligible after standard surgical care with wide local excision and appropriate lymph node sampling. Patients with stage IIb, IIc, or III melanoma who are free of disease after surgical resection are also eligible, only if they have refused high dose Interferon-alfa (INTRON A) or have had a recurrence while on Interferon-alfa.
  • Patients with choroidal melanoma may participate if they fulfill one of the following criteria: Basal diameter >16mm; Height >8mm or involvement of the ciliary body with tumor.
  • Patients must be at least 18 years of age and must be capable of understanding the consent form and giving informed consent.
  • Karnofsky Score > 80
  • Life Expectancy > 6 months
  • HLA-A1, A2, A24, or B35+ as assessed by low resolution phenotyping
  • White blood cell count ≥ 2,000/mm3
  • Platelet count ≥ 100,000/mm3
  • Neutrophil count ≥ 1,000/mm3
  • Hemoglobin ≥ 9.0 g/dL
  • Serum AST and ALT ≤ 2.5 times upper limit of normal (ULN)
  • Serum Bilirubin ≤ 2.0 mg/dL
  • Serum Creatinine ≤ 2.0 mg/dL
  • Serum Alkaline Phosphatase < 2.5 times ULN
  • Serum Creatine phosphokinase (CPK) < 2.5 times ULN

Exclusion Criteria:

  • Documented metastases in brain
  • Clinical history of HIV, HepB, HepC, and/or HTLV I.
  • Active autoimmune disease other than vitiligo
  • Patients previously immunized using the tyrosinase DNA sequence, protein, or peptides.
  • Systemic immunosuppressive therapy (corticosteroids, or other immunosuppressive drugs) within the previous 28 days
  • Surgery and/or radiotherapy within the previous 28 days
  • Chemotherapy and/or biotherapy within the previous 28 days
  • Participation in an investigational study within previous 28 days
  • Patients with cardiac demand pacemakers.
  • Women who are pregnant or < 3 months post partum or nursing.
  • Women of child-bearing potential and sexually active men must be using appropriate contraception during the course of this study.
  • Any other concurrent medical condition that in the opinion of the Principal Investigator or co-Principal Investigator's would preclude study compliance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00471133

Layout table for location information
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Ichor Medical Systems Incorporated
Memorial Sloan Kettering Cancer Center
Layout table for investigator information
Principal Investigator: Jedd D. Wolchok, MD, PhD Memorial Sloan Kettering Cancer Center

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Drew Hannaman, Ichor Medical Systems, Inc. Identifier: NCT00471133     History of Changes
Obsolete Identifiers: NCT00466427
Other Study ID Numbers: 07-003
First Posted: May 9, 2007    Key Record Dates
Last Update Posted: June 7, 2011
Last Verified: June 2011
Keywords provided by Ichor Medical Systems Incorporated:
DNA vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Immunologic Factors
Physiological Effects of Drugs